PARP1 and neoplasm: Accordingly, the demonstration that PARP inhibitors are active, relatively non-toxic anticancer agents (17–, , , 21) led to substantial enthusiasm for developing these agents to treat a variety of neoplasms that exhibit HR deficiency.